The Efficacy and Safety of Clazakizumab, an Anti–Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

Arthritis and Rheumatology

Volumn 68, Issue 9, 2016, Pages 2163-2173

  Mease, Philip J ^a   Gottlieb, Alice B ^b   Berman, Alberto ^c   Drescher, Edit ^d   Xing, Jun ^e   Wong, Robert ^e   Banerjee, Subhashis ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Section of Rheumatology   (Argentina)

^d Csolnoky Hospital   (Hungary)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAZAKIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; GLUCOCORTICOID; INTERLEUKIN 6; LIPID; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STEROID;

ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY 20; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; COMPOSITE PSORIATIC ARTHRITIS DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DACTYLITIS; DAS28; DERMATOLOGY LIFE QUALITY INDEX; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGENICITY; INJECTION SITE REACTION; LEEDS ENTHESITIS INDEX; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MUSCLE WEAKNESS; NEUTROPENIA; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE; PSORIATIC ARTHRITIS RESPONSE CRITERIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; SPONDYLARTHRITIS RESEARCH CONSORTIUM OF CANADA ENTHESITIS INDEX; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84983500182     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39700     Document Type: Article

References (29)

1. Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8:538–42.
2. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:6367–71.
3. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518–23.
4. Alenius GM, Eriksson C, Rantapää Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol 2009;27:120–3.
5. Spadaro A, Taccari E, Riccieri V, Sensi F, Sili Scavalli A, Zoppini A. Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Clin Exp Rheumatol 1996;14:413–6.
6. Van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006;65:1551–7.
7. Costa L, Caso F, Cantarini L, Del PA, Scarpa R, Atteno M. Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clin Rheumatol 2014;33:1355–7.
8. Jayasekera P, Parslew R, Al-Sharqi A. A case of tumour necrosis factor-alpha inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab. Br J Dermatol 2014;171:1546–9.
9. Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012;79:85–7.
10. Hughes M, Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford) 2013;52:1728–9.
11. Weinblatt M, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, et al. A Phase IIb study of the efficacy and safety of subcutaneous clazakizumab (anti-IL-6 monoclonal antibody) with or without methotrexate in adults with moderate-to-severe active rheumatoid arthritis and an inadequate response to methotrexate [abstract]. Arthritis Rheum 2013;65 Suppl 10:1735.
12. Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012;71:1183–9.
13. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
14. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
15. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica 1978;157:238–44.
16. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
17. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
18. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39:2013–20.
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–6.
20. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686–91.
21. Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009;68:948–53.
22. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272–7.
23. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
24. Van Riel PL. Disease Activity Score in rheumatoid arthritis. URL: http://www.das-score.nl/www.das-score.nl/index.html.
25. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986–91.
26. Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 2011;38:2461–5.
27. Neuner P, Urbanski A, Trautinger F, Moller A, Kirnbauer R, Kapp A, et al. Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol 1991;97:27–33.
28. Winchester R, Minevich G, Steshenko V, Kirby B, Kane D, Greenberg DA, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 2012;64:1134–44.
29. Song J, Boscardin WJ, Furst DE, Khanna D, Wong WK. A cautionary tale: dealing with missing data in clinical trials for rheumatic diseases. Clin Exp Rheumatol 2014;32:S122–6.